Immuneering (NASDAQ:IMRX) Sees Unusually-High Trading Volume – Here’s What Happened

Immuneering Corporation (NASDAQ:IMRX) shares saw strong trading volume on Wednesday . 1,529,284 shares traded hands during trading, an increase of 43% from the previous session’s volume of 1,067,995 shares.The stock last traded at $7.9140 and had previously closed at $6.72.

Analyst Upgrades and Downgrades

Several research firms have recently issued reports on IMRX. Leerink Partners initiated coverage on Immuneering in a research report on Friday, October 31st. They set an “outperform” rating and a $15.00 price objective for the company. HC Wainwright reiterated a “buy” rating and set a $11.00 price target on shares of Immuneering in a report on Tuesday, September 30th. Wall Street Zen downgraded Immuneering from a “hold” rating to a “sell” rating in a research note on Saturday, December 20th. Needham & Company LLC upped their target price on Immuneering from $8.00 to $11.00 and gave the company a “buy” rating in a research report on Monday, September 15th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Immuneering in a report on Monday, December 29th. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Immuneering presently has a consensus rating of “Moderate Buy” and a consensus target price of $16.50.

Immuneering Stock Performance

The business has a 50 day simple moving average of $6.62 and a 200-day simple moving average of $5.72. The firm has a market cap of $522.37 million, a price-to-earnings ratio of -4.54 and a beta of 0.48.

Immuneering (NASDAQ:IMRX) last posted its earnings results on Wednesday, November 12th. The company reported ($0.38) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.37) by ($0.01). As a group, research analysts anticipate that Immuneering Corporation will post -1.86 earnings per share for the current year.

Institutional Trading of Immuneering

Hedge funds have recently bought and sold shares of the business. Sanofi purchased a new stake in shares of Immuneering during the 3rd quarter valued at $18,960,000. Vanguard Group Inc. grew its position in Immuneering by 128.5% during the third quarter. Vanguard Group Inc. now owns 2,415,244 shares of the company’s stock valued at $16,907,000 after buying an additional 1,358,322 shares during the period. Citadel Advisors LLC bought a new position in Immuneering during the third quarter valued at about $6,602,000. Blue Owl Capital Holdings LP purchased a new stake in Immuneering during the third quarter worth about $3,850,000. Finally, Monashee Investment Management LLC bought a new stake in Immuneering in the third quarter worth about $2,100,000. 67.65% of the stock is currently owned by institutional investors.

Immuneering Company Profile

Immuneering (Nasdaq: IMRX) is a clinical-stage biopharmaceutical company leveraging artificial intelligence and its proprietary RABIT (Repurposing and Accelerating Biotechnology Tools) platform to design and optimize small-molecule and peptide therapies. By analyzing large-scale biomedical datasets, Immuneering’s machine learning algorithms identify novel drug–target interactions, repurpose existing drug scaffolds and accelerate lead candidate selection. The company’s AI-driven approach aims to reduce development timelines and improve therapeutic profiles in areas of high unmet medical need.

The company’s lead program, IRX-2, is a small-molecule candidate currently in Phase 2 clinical trials for the treatment of painful diabetic peripheral neuropathy.